← 產業報告目錄

Apheresis Market by Product (Device, Disposable), Procedure [Donor, Therapeutic (Neurological, Blood)], Application (Plasmapheresis, Plateletpheresis), Technology (Centrifugation, Membrane Separation), End User (Clinic) - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-06-05頁數 330報告編號 MD1407

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global apheresis market is projected to reach USD 4.41 billion by 2031 from USD 3.02 billion in 2026, growing at a CAGR of 7.9% during the forecast period. The demand for apheresis equipment and techniques is growing steadily, driven by the rising incidence of hematological, autoimmune, neurological, and renal diseases, as well as the high demand for blood components and plasma-based products worldwide. Increasing use of therapeutic and donor apheresis techniques in hospitals, blood banks, and specialized clinics is supporting the growth of the market. Healthcare facilities are now focusing on developing highly efficient, fully automated, and patient-friendly apheresis systems to increase collection efficacy and improve patient outcomes. Additionally, technological innovations, including automated blood component separators and continuous flow centrifuges, are contributing to market growth. Moreover, improved blood collection facilities in developing countries and healthcare organizations' initiatives ensure effective blood management and are expected to sustain strong market growth in the coming years. “By product, the disposables are projected to capture a significant market share.” By product, the disposables category holds the largest share of the global apheresis market, driven by rising numbers of blood collections and therapeutic apheresis procedures worldwide. Disposable kits, tubing assemblies, needles, and collection chambers are vital components of apheresis systems, as they ensure sterility, minimize the risk of contamination, and safeguard patients and donors. The repeated consumption of disposables and their replacement at each new apheresis procedure play a significant role in generating consistent revenue and ensuring product demand. The growing number of plasma collection, plateletpheresis, leukapheresis, and therapeutic plasma exchange procedures is another important factor driving growth in the disposables category. In addition, the increasing demand for plasma-based therapeutics, the rise in blood donations, and the growing acceptance of automated apheresis technology are contributing to the growing use of disposables. “By procedure, the plasmapheresis segment is expected to register the highest share in 2025.” By procedure, the plasmapheresis segment holds the largest market share in the apheresis market, driven by growing worldwide demand for plasma-derived therapies used to treat immunological, neurological, and hematological conditions. The plasmapheresis method is widely applied for obtaining donor plasma as well as conducting plasma exchange therapy, since it is highly efficient in plasma separation and collection while other components of the blood are returned to the body. Growth in the incidence of autoimmune diseases, higher demand for immunoglobulins and coagulation factors, and an increasing number of plasma donations worldwide are additional factors supporting the segment's growth. Additionally, the widespread use of plasmapheresis procedures in blood centers and hospitals is facilitated by recent developments in automated plasmapheresis technology, which increase process efficiency and improve donor safety and productivity. In 2025, North America accounted for the largest market share of the apheresis market by region. The apheresis market is segmented into North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa. North America leads the global apheresis market; this dominance is attributed to the high incidence of hematological, autoimmune, neurological, and renal disorders, as well as robust demand for plasma-based products and blood components. The region benefits from an extensive healthcare and blood donation network, widespread use of apheresis techniques, and the involvement of major market players and plasma collection companies. In addition, increased awareness of blood donation, rising cases of apheresis treatment, favorable reimbursement policies, and investment in transfusion medicine and plasma collection facilities contribute to the market's dominance in the region. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1–40%, Tier 2–35%, and Tier 3– 25% • By Designation: Directors–23%, Managers–30%, and Others–47% • By Region: North America–25%, Europe–35%, the Asia Pacific–20%, Latin America- 13%, and the Middle East & Africa- 7% The prominent players in the apheresis market include Terumo Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Fresenius Medical Care AG (Germany), Asahi Kasei Medical Co., Ltd. (Japan), Becton, Dickinson and Company (US), Macopharma SA (France), Miltenyi Biotec (Germany), Therakos LLC (US), Toray Industries Inc. (Japan), Kaneka Corporation (Japan), and B. Braun SE (Germany). Research Coverage This report examines the apheresis market by product, type, procedure, technology, end user, and region. It also covers the factors affecting market growth, analyzes the opportunities and challenges in the market, and provides details on the competitive landscape among market leaders. Furthermore, the report analyzes micro-markets by their individual growth trends and forecasts revenue for market segments across five main regions (and the countries within these regions). Reasons to Buy the Report The report will enable established firms, as well as entrants/smaller firms, to gauge the market pulse, which, in turn, will help them gain a larger market share. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market presence. This report provides insights into the following pointers: Analysis of key drivers (rising prevalence of autoimmune and neurological disorders, increasing utilization of plasma-derived biologics by biopharmaceutical companies, rising demand for blood components, increasing emphasis on transfusion safety, growing volume of complex oncological and transplant procedures, technological improvements in component-specific blood collection, and expanding adoption of cell and gene therapies), restraints (high procedural and operational costs limiting adoption of apheresis technologies, limited adoption of apheresis donation procedures in emerging economies, stringent donor eligibility criteria and limited donor availability restraining apheresis procedures and dearth of skilled professionals impacting the adoption of apheresis procedures), opportunities (adoption of apheresis procedures in leukemia and pediatric patients creating growth opportunities for the apheresis market, and growing investments in emerging markets by governments and key industry players), and challenges (risk of procedure-related adverse events and risk of transfusion-transmitted infections and inadequate blood screening infrastructure in emerging countries) influencing the growth of apheresis market • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the apheresis market • Product Development/Innovation: Detailed insights into the upcoming trends, R&D activities, and product developments in the apheresis market • Market Development: Comprehensive information on lucrative emerging regions • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the apheresis market • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
目錄 Table of Contents
1 INTRODUCTION 30 1.1 STUDY OBJECTIVES 30 1.2 MARKET DEFINITION 30 1.2.1 PRODUCT DEFINITION 31 1.2.2 TECHNOLOGY DEFINITION 31 1.2.3 PROCEDURE DEFINITION 31 1.2.4 END USER DEFINITION 32 1.2.5 INCLUSIONS & EXCLUSIONS 33 1.3 STUDY SCOPE 34 1.3.1 MARKET SEGMENTATION 34 1.3.2 YEARS CONSIDERED 35 1.3.3 CURRENCY CONSIDERED 35 1.4 STAKEHOLDERS 35 1.5 SUMMARY OF CHANGES 36 2 EXECUTIVE SUMMARY 37 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 37 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 39 2.3 DISRUPTIVE TRENDS IN APHERESIS MARKET 40 2.4 HIGH-GROWTH SEGMENTS 40 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 41 3 PREMIUM INSIGHTS 42 3.1 APHERESIS MARKET OVERVIEW 42 3.2 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY AND END USER 43 3.3 GEOGRAPHIC SNAPSHOT OF APHERESIS MARKET 44 4 MARKET OVERVIEW 45 4.1 INTRODUCTION 45 4.2 MARKET DYNAMICS 45 4.2.1 DRIVERS 46 4.2.1.1 Rising prevalence of autoimmune and neurological disorders driving demand for therapeutic apheresis procedures 46 4.2.1.2 Rising demand for blood components and increasing emphasis on transfusion safety to support market expansion 46 4.2.1.3 Growing volume of complex oncological and transplant procedures to support growth of apheresis 47 4.2.1.4 Technological improvements in component-specific blood collection to support market expansion 48 4.2.1.5 Expanding adoption of cell and gene therapies to create growth opportunities for apheresis market 48 4.2.2 RESTRAINTS 49 4.2.2.1 High procedural and operational costs limit adoption of apheresis technologies 49 4.2.2.2 Limited adoption of apheresis donation procedures in emerging economies 50 4.2.2.3 Stringent donor eligibility criteria and limited donor availability to restrain apheresis procedures 50 4.2.2.4 Dearth of skilled professionals impacting adoption of apheresis procedures 51 4.2.3 OPPORTUNITIES 52 4.2.3.1 Adoption of apheresis procedures in leukemia and pediatric patients creating growth opportunities 52 4.2.3.2 Growing investments in emerging markets by governments and key industry players 52 4.2.4 CHALLENGES 53 4.2.4.1 Risk of procedure-related adverse events and donor safety concerns 53 4.2.4.2 Risk of transfusion-transmitted infections and inadequate blood screening infrastructure in emerging countries 54 4.3 UNMET NEEDS AND WHITE SPACES 54 4.3.1 UNMET NEEDS IN APHERESIS MARKET 54 4.3.2 WHITE SPACE OPPORTUNITIES 55 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 57 4.4.1 INTERCONNECTED MARKETS 57 4.4.2 CROSS-SECTOR OPPORTUNITIES 58 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 58 4.5.1 STRATEGIC MOVES IN APHERESIS MARKET 59 5 INDUSTRY TRENDS 60 5.1 PORTER’S FIVE FORCES ANALYSIS 60 5.1.1 THREAT FROM NEW ENTRANTS 61 5.1.2 THREAT FROM SUBSTITUTES 61 5.1.3 BARGAINING POWER OF SUPPLIERS 62 5.1.4 BARGAINING POWER OF BUYERS 62 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 63 5.2 MACROECONOMIC INDICATORS 63 5.2.1 INTRODUCTION 63 5.2.2 GDP TRENDS AND FORECAST 63 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 64 5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY 65 5.3 SUPPLY CHAIN ANALYSIS 65 5.4 VALUE CHAIN ANALYSIS 66   5.5 ECOSYSTEM ANALYSIS 67 5.5.1 MANUFACTURERS 68 5.5.2 END USERS 69 5.5.3 REGULATORY BODIES 69 5.6 PRICING ANALYSIS 70 5.7 TRADE ANALYSIS 71 5.7.1 IMPORT DATA (HS CODE 901890) 71 5.7.2 EXPORT DATA FOR (HS CODE 901890) 71 5.8 REIMBURSEMENT SCENARIO 72 5.9 KEY CONFERENCES & EVENTS, 2026–2027 74 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 74 5.11 INVESTMENT & FUNDING SCENARIO 75 5.12 CASE STUDY ANALYSIS 76 5.13 IMPACT OF 2025 US TARIFF 77 5.13.1 INTRODUCTION 77 5.13.2 KEY TARIFF RATES 78 5.13.3 PRICE IMPACT ANALYSIS 78 5.13.4 IMPACT ON COUNTRY/REGION 79 5.13.5 IMPACT ON END-USE SEGMENTS 80 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 82 6.1 TECHNOLOGY ANALYSIS 82 6.1.1 KEY EMERGING TECHNOLOGIES 82 6.1.1.1 Automation and AI-enabled procedure optimization in apheresis systems 82 6.1.1.2 Closed-loop and automated cell therapy collection/manufacturing workflows 82 6.1.2 COMPLEMENTARY TECHNOLOGIES 83 6.1.2.1 Real-time biosensors and digital monitoring in apheresis procedures 83 6.1.2.2 RFID, barcode, and digital traceability technologies in blood and cell collection management 83 6.1.3 ADJACENT TECHNOLOGIES 84 6.1.3.1 Cell and gene therapy manufacturing technologies 84 6.1.3.2 Therapeutic filtration, adsorption, and extracorporeal blood purification technologies 84 6.2 TECHNOLOGY/PRODUCT ROADMAP 84 6.2.1 NEAR TERM (2025–2027) 85 6.2.2 MID-TERM (2028–2030) 85 6.2.3 LONG TERM (2030+) 85 6.3 PATENT ANALYSIS 86 6.3.1 JURISDICTION AND TOP APPLICANT ANALYSIS 86   6.4 FUTURE APPLICATIONS 88 6.4.1 AI-ENABLED AND DATA-DRIVEN APHERESIS PROCEDURE OPTIMIZATION 88 6.4.2 PERSONALIZED THERAPEUTIC APHERESIS 88 6.4.3 CONNECTED APHERESIS WORKFLOWS AND DIGITAL TRACEABILITY 89 6.5 IMPACT OF AI/GEN AI ON APHERESIS 89 6.5.1 INTRODUCTION 89 6.5.2 MARKET POTENTIAL OF AI IN APHERESIS 89 6.5.3 AI USE CASES 90 6.5.4 KEY COMPANIES IMPLEMENTING AI 91 7 SUSTAINABILITY & REGULATORY LANDSCAPE 93 7.1 REGULATORY LANDSCAPE 93 7.1.1 REGULATORY FRAMEWORK 93 7.1.1.1 North America 93 7.1.1.2 Europe 93 7.1.1.3 Asia Pacific 94 7.1.1.4 Latin America 94 7.1.1.5 Middle East & Africa 94 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95 7.1.3 INDUSTRY STANDARDS 97 7.2 SUSTAINABILITY INITIATIVES 98 7.2.1 REDUCING SINGLE-USE APHERESIS WASTE 98 7.2.2 USE OF LOWER-IMPACT MATERIALS AND PACKAGING 98 7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 98 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 100 8.1 KEY STAKEHOLDERS & BUYING CRITERIA 100 8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS 100 8.1.2 BUYING CRITERIA 101 8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 102 8.2.1 DECISION-MAKING PROCESS 102 8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 102 8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 103 8.2.4 MARKET PROFITABILITY 103 9 APHERESIS MARKET, BY TYPE 105 9.1 INTRODUCTION 106 9.2 DONOR APHERESIS 106 9.2.1 INCREASING BLOOD DONATIONS AND EXPANDING CELL THERAPY COLLECTIONS TO SUPPORT DONOR APHERESIS MARKET GROWTH 106   9.3 THERAPEUTIC APHERESIS 109 9.3.1 GROWING CLINICAL UTILIZATION OF THERAPEUTIC PLASMA EXCHANGE AND EXPANDING NEUROLOGICAL APPLICATIONS TO DRIVE MARKET 109 9.4 NEUROLOGICAL DISORDERS 111 9.4.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH 111 9.5 BLOOD DISORDERS 112 9.5.1 RISING PREVALENCE OF HEMATOLOGICAL AND GENETIC BLOOD DISORDERS TO DRIVE DEMAND 112 9.6 RENAL DISORDERS 114 9.6.1 RISING BURDEN OF CHRONIC KIDNEY DISEASE AND AUTOIMMUNE RENAL COMPLICATIONS TO DRIVE DEMAND 114 9.7 AUTOIMMUNE DISORDERS 116 9.7.1 INCREASING PREVALENCE OF AUTOIMMUNE DISORDERS AND CONTINUED CLINICAL IMPORTANCE OF THERAPEUTIC APHERESIS TO DRIVE GROWTH 116 9.8 METABOLIC DISORDERS 117 9.8.1 GROWING BURDEN OF DIABETES AND METABOLIC CONDITIONS TO SUPPORT THERAPEUTIC APHERESIS MARKET GROWTH 117 9.9 CARDIOVASCULAR DISORDERS 119 9.9.1 RISING LONG-TERM BURDEN OF CARDIOVASCULAR DISORDERS TO DRIVE MARKET GROWTH 119 9.10 OTHER DISORDERS 120 10 APHERESIS MARKET, BY END USER 122 10.1 INTRODUCTION 123 10.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS 123 10.2.1 INCREASING DEMAND FOR COMPONENT-SPECIFIC BLOOD COLLECTION AND COMMERCIAL PLASMA SUPPLY TO DRIVE MARKET GROWTH 123 10.3 HOSPITALS & TRANSFUSION CENTERS 125 10.3.1 EXPANDING TRANSFUSION REQUIREMENTS IN ONCOLOGY, TRANSPLANT, AND CRITICAL CARE SETTINGS TO DRIVE MARKET GROWTH 125 10.4 OTHER END USERS 126 11 APHERESIS MARKET, BY PROCEDURE 128 11.1 INTRODUCTION 129 11.2 PLASMAPHERESIS 129 11.2.1 INCREASING GLOBAL DEMAND FOR PLASMA-DERIVED THERAPIES AND THERAPEUTIC PLASMA EXCHANGE TO DRIVE MARKET GROWTH 129 11.3 PLATELETAPHERESIS 132 11.3.1 INCREASING DEMAND FOR PLATELET TRANSFUSIONS IN ONCOLOGY, TRANSPLANT, AND CRITICAL CARE SETTINGS TO DRIVE MARKET GROWTH 132 11.4 ERYTHROCYTAPHERESIS 134 11.4.1 INCREASING BURDEN OF SICKLE CELL DISEASE AND RISING DEMAND FOR TARGETED RED BLOOD CELL EXCHANGE PROCEDURES TO DRIVE GROWTH 134   11.5 LEUKAPHERESIS 136 11.5.1 EXPANDING CELL AND GENE THERAPY PIPELINE AND INCREASING CAR-T CELL MANUFACTURING ACTIVITIES TO DRIVE MARKET GROWTH 136 11.6 PHOTOPHERESIS 137 11.6.1 INCREASING TRANSPLANT PROCEDURES AND RISING USE OF IMMUNE-MODULATING THERAPIES TO SUPPORT MARKET GROWTH 137 11.7 OTHER PROCEDURES 139 12 APHERESIS MARKET, BY PRODUCT 141 12.1 INTRODUCTION 142 12.2 APHERESIS DEVICES 143 12.2.1 RISING DEMAND FOR PLASMA-DERIVED THERAPIES TO DRIVE SEGMENT GROWTH 143 12.3 APHERESIS DISPOSABLES 144 12.3.1 RECURRING UTILIZATION OF SINGLE-USE CONSUMABLES AND RISING THERAPEUTIC PROCEDURE VOLUMES TO DRIVE GROWTH 144 13 APHERESIS MARKET, BY TECHNOLOGY 147 13.1 INTRODUCTION 148 13.2 CENTRIFUGATION 148 13.3 CONTINUOUS FLOW CENTRIFUGATION 150 13.3.1 INCREASING NEED FOR HIGH-THROUGHPUT BLOOD COMPONENT COLLECTION AND EFFICIENT PLASMA PROCESSING TO DRIVE GROWTH 150 13.4 INTERMITTENT FLOW CENTRIFUGATION 152 13.4.1 INCREASING DEMAND FOR COST-EFFECTIVE AND FLEXIBLE APHERESIS SYSTEMS IN HEALTHCARE SETTINGS TO SUPPORT MARKET GROWTH 152 13.5 MEMBRANE SEPARATION 154 13.5.1 INCREASING UTILIZATION OF MEMBRANE-BASED PLASMA FILTRATION TECHNOLOGIES IN THERAPEUTIC APHERESIS TO DRIVE MARKET GROWTH 154 14 APHERESIS MARKET, BY REGION 156 14.1 INTRODUCTION 157 14.2 NORTH AMERICA 157 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 158 14.2.2 US 162 14.2.2.1 Strong economic capacity and high healthcare spending to support north america apheresis market growth 162 14.2.3 CANADA 164 14.2.3.1 Rising demand for blood components and plasma protein products to drive market growth 164 14.3 ASIA PACIFIC 167 14.3.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 167 14.3.2 CHINA 171 14.3.2.1 Expanding healthcare infrastructure and growing demand for advanced blood management procedures to accelerate growth 171 14.3.3 JAPAN 173 14.3.3.1 Aging-driven treatment demand and advanced hospital infrastructure to support market growth 173 14.3.4 INDIA 175 14.3.4.1 Large patient base and expanding healthcare infrastructure to drive market 175 14.3.5 AUSTRALIA 178 14.3.5.1 Strong healthcare infrastructure and growing demand for specialized therapies to support market growth 178 14.3.6 SOUTH KOREA 180 14.3.6.1 Advanced healthcare technologies and growing specialty care adoption to support market growth 180 14.3.7 THAILAND 182 14.3.7.1 Expanding specialty care infrastructure and rising chronic disease burden to support market growth 182 14.3.8 SINGAPORE 185 14.3.8.1 Advanced healthcare infrastructure and regional medical hub status to support market growth 185 14.3.9 REST OF ASIA PACIFIC 187 14.4 EUROPE 189 14.4.1 MACROECONOMIC OUTLOOK FOR EUROPE 189 14.4.2 GERMANY 192 14.4.2.1 High healthcare spending and strong reimbursement support to drive market growth 192 14.4.3 FRANCE 194 14.4.3.1 Centralized healthcare system and growing therapeutic apheresis utilization to propel growth 194 14.4.4 ITALY 196 14.4.4.1 Rising elderly population and growing demand for therapeutic procedures to drive growth 196 14.4.5 UK 198 14.4.5.1 Expanding apheresis infrastructure and specialized care services to support market growth 198 14.4.6 SPAIN 200 14.4.6.1 Growing chronic disease burden and expanding specialty treatment centers to support market growth 200 14.4.7 SWITZERLAND 202 14.4.7.1 Advanced healthcare funding and specialized treatment capabilities to support growth 202 14.4.8 NETHERLANDS 204 14.4.8.1 Advanced healthcare infrastructure and strong academic network to support market 204 14.4.9 REST OF EUROPE 206   14.5 LATIN AMERICA 208 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 208 14.5.2 BRAZIL 211 14.5.2.1 Cancer burden, blood donation recovery, and CAR-T access to strengthen market growth 211 14.5.3 MEXICO 213 14.5.3.1 Expanding leukemia treatment access and rising blood component demand to support market growth 213 14.5.4 REST OF LATIN AMERICA 216 14.6 MIDDLE EAST & AFRICA 218 14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 218 14.6.2 GCC COUNTRIES 221 14.6.2.1 Expanding advanced healthcare infrastructure and cell therapy capabilities to support market 221 14.6.3 KINGDOM OF SAUDI ARABIA (KSA) 223 14.6.3.1 Expanding cell therapy infrastructure and clinical trial ecosystem to support market growth 223 14.6.3.2 United Arab Emirates (UAE) 225 14.6.3.2.1 Growing precision medicine initiatives and advanced oncology capabilities to support market growth 225 14.6.4 OTHER GCC COUNTRIES 227 14.6.5 REST OF MIDDLE EAST & AFRICA 229 15 COMPETITIVE LANDSCAPE 232 15.1 INTRODUCTION 232 15.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023–2026 232 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN APHERESIS MARKET 232 15.3 REVENUE ANALYSIS, 2023–2025 233 15.4 GLOBAL MARKET SHARE ANALYSIS, 2025 234 15.4.1 US: MARKET SHARE ANALYSIS, 2025 236 15.4.2 EUROPE: MARKET SHARE ANALYSIS, 2025 236 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 237 15.5.1 STARS 238 15.5.2 EMERGING LEADERS 238 15.5.3 PERVASIVE PLAYERS 238 15.5.4 PARTICIPANTS 238 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 240 15.5.5.1 Company footprint 240 15.5.5.2 Region footprint 240 15.5.5.3 Product footprint 241 15.5.5.4 Type footprint 241 15.5.5.5 Technology footprint 242   15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 243 15.6.1 PROGRESSIVE COMPANIES 243 15.6.2 RESPONSIVE COMPANIES 243 15.6.3 DYNAMIC COMPANIES 243 15.6.4 STARTING BLOCKS 243 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 244 15.7 COMPANY VALUATION AND FINANCIAL METRICS 246 15.7.1 FINANCIAL METRICS 246 15.7.2 COMPANY VALUATION 246 15.8 BRAND/PRODUCT COMPARISON 247 15.9 COMPETITIVE SCENARIO 247 15.9.1 PRODUCT LAUNCHES & APPROVALS 247 15.9.2 DEALS 248 15.9.3 EXPANSIONS 250 16 COMPANY PROFILES 251 16.1 KEY PLAYERS (APHERESIS PRODUCTS MARKET) 251 16.1.1 TERUMO CORPORATION 251 16.1.1.1 Business overview 251 16.1.1.2 Products offered 252 16.1.1.3 Recent developments 254 16.1.1.3.1 Product launches & approvals 254 16.1.1.3.2 Deals 254 16.1.1.3.3 Expansions 255 16.1.1.4 MnM view 255 16.1.1.4.1 Right to win 255 16.1.1.4.2 Strategic choices 256 16.1.1.4.3 Weaknesses & competitive threats 256 16.1.2 FRESENIUS SE & CO. KGAA 257 16.1.2.1 Business overview 257 16.1.2.2 Products offered 258 16.1.2.3 Recent developments 260 16.1.2.3.1 Product launches 260 16.1.2.3.2 Other developments 261 16.1.2.4 MnM view 261 16.1.2.4.1 Key strengths 261 16.1.2.4.2 Strategic choices 261 16.1.2.4.3 Weaknesses and competitive threats 261   16.1.3 FRESENIUS MEDICAL CARE AG 262 16.1.3.1 Business overview 262 16.1.3.2 Products offered 263 16.1.3.3 Recent developments 264 16.1.3.4 MnM view 264 16.1.3.4.1 Key strengths/Right to win 264 16.1.3.4.2 Strategic choices 264 16.1.3.4.3 Weaknesses and competitive threats 265 16.1.4 HAEMONETICS CORPORATION 266 16.1.4.1 Business overview 266 16.1.4.2 Products offered 267 16.1.4.3 Recent developments 268 16.1.4.3.1 Product launches 268 16.1.4.4 MnM view 268 16.1.4.4.1 Key strengths/Right to win 268 16.1.4.4.2 Strategic choices 269 16.1.4.4.3 Weaknesses and competitive threats 269 16.1.5 B. BRAUN SE 270 16.1.5.1 Business overview 270 16.1.5.2 Products offered 271 16.1.5.3 MnM view 273 16.1.5.3.1 Key strengths/Right to win 273 16.1.5.3.2 Strategic choices 273 16.1.5.3.3 Weaknesses and competitive threats 273 16.1.6 BD 274 16.1.6.1 Business overview 274 16.1.6.2 Products offered 274 16.1.6.3 Recent developments 276 16.1.6.3.1 Deals 276 16.1.6.3.2 Expansions 276 16.1.7 ASAHI KASEI MEDICAL CO., LTD. 277 16.1.7.1 Business overview 277 16.1.7.2 Products offered 277 16.1.7.3 Recent developments 278 16.1.7.3.1 Other developments 278 16.1.8 OTSUKA HOLDINGS CO., LTD. 279 16.1.8.1 Business overview 279 16.1.8.2 Products offered 280 16.1.9 MEDICA S.P.A 281 16.1.9.1 Business overview 281 16.1.9.2 Products offered 281   16.1.10 SUMITOMO BAKELITE CO., LTD. 282 16.1.10.1 Business overview 282 16.1.10.2 Products offered 283 16.1.10.3 MnM view 284 16.1.10.3.1 Right to win 284 16.1.10.3.2 Strategic choices 284 16.1.10.3.3 Weaknesses & competitive threats 284 16.1.11 KANEKA CORPORATION 285 16.1.11.1 Business overview 285 16.1.11.2 Products offered 286 16.1.11.3 Recent developments 288 16.1.11.3.1 Deals 288 16.1.11.3.2 Expansions 288 16.1.12 VANTIVE 289 16.1.12.1 Business overview 289 16.1.12.2 Products offered 289 16.1.12.3 Recent developments 290 16.1.12.3.1 Deals 290 16.1.12.3.2 Other developments 291 16.1.13 MILTENYI BIOTEC 292 16.1.13.1 Business overview 292 16.1.13.2 Products offered 292 16.1.13.3 Recent developments 293 16.1.13.3.1 Deals 293 16.1.13.3.2 Expansions 294 16.1.14 NIKKISO CO., LTD. 295 16.1.14.1 Business overview 295 16.1.14.2 Products offered 296 16.1.14.3 Recent developments 297 16.1.14.3.1 Deals 297 16.1.14.3.2 Other developments 297 16.1.15 TORAY INDUSTRIES, INC. 298 16.1.15.1 Business overview 298 16.1.15.2 Products offered 299 16.2 OTHER PLAYERS 300 16.2.1 MACOPHARMA SA 300 16.2.2 INFOMED SA 301 16.2.3 THERAKOS LLC. 301 16.2.4 MEDICAP GMBH 302 16.2.5 HAIER BIOMEDICAL 302 16.2.6 SICHUAN NIGALE BIOTECHNOLOGY CO, LTD. 303 16.2.7 JAFRON BIOMEDICAL CO., LTD. 304 16.2.8 SHANGHAI DAHUA MEDICAL APPARATUS CO., LTD 305 16.2.9 KENTEC MEDICAL 306 16.2.10 SCINOMED LTD. 306 17 RESEARCH METHODOLOGY 307 17.1 RESEARCH DATA 307 17.1.1 SECONDARY DATA 308 17.1.1.1 Key data from secondary sources 309 17.1.2 PRIMARY DATA 310 17.1.2.1 Key industry insights 311 17.2 MARKET SIZE ESTIMATION METHODOLOGY 313 17.3 MARKET GROWTH RATE PROJECTIONS 316 17.4 DATA TRIANGULATION 318 17.5 RESEARCH ASSUMPTIONS 318 17.5.1 GROWTH RATE ASSUMPTIONS 319 17.6 RISK ASSESSMENT 319 17.7 LIMITATIONS 319 17.7.1 METHODOLOGY-RELATED LIMITATIONS 319 17.7.2 SCOPE-RELATED LIMITATIONS 319 17.8 RESEARCH LIMITATIONS 320 17.9 RISK ANALYSIS 320 18 APPENDIX 321 18.1 DISCUSSION GUIDE 321 18.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 326 18.3 CUSTOMIZATION OPTIONS 328 18.3.1 COMPANY INFORMATION 328 18.3.2 COUNTRY ANALYSIS 328 18.3.3 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 328 18.3.4 COUNTRY-LEVEL VOLUME ANALYSIS 328 18.3.5 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 328 18.4 RELATED REPORTS 328 18.5 AUTHOR DETAILS 329
圖表清單 List of Tables & Figures
TABLE 1 CURRENCY CONVERSION RATES, 2023–2026 35 TABLE 2 INDICATIVE BLOOD AND BLOOD COMPONENT UTILIZATION ACROSS MAJOR SURGICAL AND CLINICAL CONDITIONS 47 TABLE 3 ESTIMATED BLOOD DONATIONS, BY REGION, 2024–2025 50 TABLE 4 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS 51 TABLE 5 RECENT INVESTMENTS AND STRATEGIC ACTIVITIES IN CELL & GENE THERAPY ECOSYSTEM 53 TABLE 6 APHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 60 TABLE 7 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION) 63 TABLE 8 LIST OF KEY APHERESIS MANUFACTURERS 68 TABLE 9 LIST OF KEY END USERS 69 TABLE 10 LIST OF KEY REGULATORY BODIES 69 TABLE 11 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2023–2025 (USD) 70 TABLE 12 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 (USD) 70 TABLE 13 IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 71 TABLE 14 EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 71 TABLE 15 KEY US BILLING CODES USED FOR APHERESIS PROCEDURES 72 TABLE 16 US AVERAGE MEDICARE OUTPATIENT PAYMENT 73 TABLE 17 APHERESIS MARKET: MAJOR CONFERENCES & EVENTS, 2026–2027 74 TABLE 18 FRESENIUS SE & CO. KGAA AMICUS APHERESIS DEVICE — THERAPEUTIC APHERESIS IN MYASTHENIA GRAVIS PATIENT 76 TABLE 19 TERUMO BCT’S SPECTRA OPTIA APHERESIS DEVICE — SWITCH FROM MANUAL TO AUTOMATED RED BLOOD CELL EXCHANGE IN BRAZIL 76 TABLE 20 TERUMO BCT + BOSTON CHILDREN’S HOSPITAL — OPTIMIZING STEM CELL COLLECTION IN SICKLE CELL DISEASE 77 TABLE 21 RECIPROCAL TARIFF RATES ADJUSTED BY US, 2024 78 TABLE 22 KEY PRODUCT-RELATED TARIFF 78 TABLE 23 NORTH AMERICA: IMPACT OF US TARIFF ON CANADA 79 TABLE 24 ASIA PACIFIC: IMPACT OF US TARIFF ON CHINA, JAPAN, AND INDIA 79 TABLE 25 EUROPE: IMPACT OF US TARIFF ON GERMANY AND UK 79 TABLE 26 LATIN AMERICA: IMPACT OF US TARIFF ON MEXICO 80 TABLE 27 APHERESIS MARKET: KEY PATENTS, 2023–2025 87 TABLE 28 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95 TABLE 29 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95 TABLE 30 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96 TABLE 31 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 32 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97 TABLE 33 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF APHERESIS 100 TABLE 34 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS, BY END USER 101 TABLE 35 APHERESIS MARKET: ADOPTION BARRIERS & INTERNAL CHALLENGES 102 TABLE 36 APHERESIS MARKET: UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 103 TABLE 37 APHERESIS MARKET: KEY PROFITABILITY DRIVERS 104 TABLE 38 APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 106 TABLE 39 DONOR APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 108 TABLE 40 THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 110 TABLE 41 THERAPEUTIC APHERESIS MARKET, BY DISEASE TYPE, 2024–2031 (USD MILLION) 111 TABLE 42 NEUROLOGICAL DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 112 TABLE 43 BLOOD DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 113 TABLE 44 RENAL DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 115 TABLE 45 AUTOIMMUNE DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 117 TABLE 46 METABOLIC DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 118 TABLE 47 CARDIOVASCULAR DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 120 TABLE 48 OTHER DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 121 TABLE 49 APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 123 TABLE 50 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 124 TABLE 51 HOSPITALS & TRANSFUSION CENTERS APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 126 TABLE 52 OTHER END USERS: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 127 TABLE 53 APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 129 TABLE 54 PLASMAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 131 TABLE 55 PLATELETAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 133 TABLE 56 ERYTHROCYTAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 135 TABLE 57 LEUKAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 137 TABLE 58 PHOTOPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 138 TABLE 59 OTHER PROCEDURES: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 140 TABLE 60 APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 142 TABLE 61 APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS) 142 TABLE 62 COMMERCIAL APHERESIS DEVICES 143 TABLE 63 APHERESIS DEVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 144 TABLE 64 COMMERCIAL APHERESIS DISPOSABLES 145 TABLE 65 APHERESIS DISPOSABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 146 TABLE 66 APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 148 TABLE 67 COMMERCIAL CENTRIFUGATION TECHNOLOGY DEVICES 148 TABLE 68 CENTRIFUGATION APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 149 TABLE 69 CONTINUOUS FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 151 TABLE 70 INTERMITTENT FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 153 TABLE 71 SIZE OF BLOOD COMPONENTS 154 TABLE 72 COMMERCIAL MEMBRANE SEPARATION DEVICES 154 TABLE 73 MEMBRANE SEPARATION APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 155 TABLE 74 APHERESIS MARKET, BY REGION, 2024–2031 (USD MILLION) 157 TABLE 75 MAJOR APHERESIS MARKET PLAYERS IN NORTH AMERICA 158 TABLE 76 NORTH AMERICA: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 77 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 160 TABLE 78 NORTH AMERICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 160 TABLE 79 NORTH AMERICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 160 TABLE 80 NORTH AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 161 TABLE 81 NORTH AMERICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 161 TABLE 82 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS) 161 TABLE 83 US: KEY MACROINDICATORS 162 TABLE 84 US: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 163 TABLE 85 US: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 163 TABLE 86 US: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 163 TABLE 87 US: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 164 TABLE 88 US: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 164 TABLE 89 CANADA: KEY MACROINDICATORS 165 TABLE 90 CANADA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 165 TABLE 91 CANADA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 165 TABLE 92 CANADA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 166 TABLE 93 CANADA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 166 TABLE 94 CANADA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 166 TABLE 95 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 96 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 169 TABLE 97 ASIA PACIFIC: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 169 TABLE 98 ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 169 TABLE 99 ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 170 TABLE 100 ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 170 TABLE 101 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS) 170 TABLE 102 CHINA: KEY MACROINDICATORS 171 TABLE 103 CHINA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 171 TABLE 104 CHINA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 172 TABLE 105 CHINA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 172 TABLE 106 CHINA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 172 TABLE 107 CHINA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 173 TABLE 108 JAPAN: KEY MACROINDICATORS 173 TABLE 109 JAPAN: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 174 TABLE 110 JAPAN: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 174 TABLE 111 JAPAN: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 174 TABLE 112 JAPAN: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 175 TABLE 113 JAPAN: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 175 TABLE 114 INDIA: KEY MACROINDICATORS 176 TABLE 115 INDIA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 176 TABLE 116 INDIA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 176 TABLE 117 INDIA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 177 TABLE 118 INDIA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 177 TABLE 119 INDIA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 177 TABLE 120 AUSTRALIA: KEY MACROINDICATORS 178 TABLE 121 AUSTRALIA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 178 TABLE 122 AUSTRALIA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 179 TABLE 123 AUSTRALIA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 179 TABLE 124 AUSTRALIA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 179 TABLE 125 AUSTRALIA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 180 TABLE 126 SOUTH KOREA: KEY MACROINDICATORS 180 TABLE 127 SOUTH KOREA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 181 TABLE 128 SOUTH KOREA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 181 TABLE 129 SOUTH KOREA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 181 TABLE 130 SOUTH KOREA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 182 TABLE 131 SOUTH KOREA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 182 TABLE 132 THAILAND: KEY MACROINDICATORS 183 TABLE 133 THAILAND: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 183 TABLE 134 THAILAND: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 183 TABLE 135 THAILAND: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 184 TABLE 136 THAILAND: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 184 TABLE 137 THAILAND: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 184 TABLE 138 SINGAPORE: KEY MACROINDICATORS 185 TABLE 139 SINGAPORE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 185 TABLE 140 SINGAPORE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 141 SINGAPORE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 186 TABLE 142 SINGAPORE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 186 TABLE 143 SINGAPORE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 187 TABLE 144 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 187 TABLE 145 REST OF ASIA PACIFIC: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 188 TABLE 146 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 188 TABLE 147 REST OF ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 188 TABLE 148 REST OF ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 189 TABLE 149 EUROPE: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 190 TABLE 150 EUROPE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 190 TABLE 151 EUROPE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 190 TABLE 152 EUROPE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 191 TABLE 153 EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 191 TABLE 154 EUROPE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 191 TABLE 155 EUROPE: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS) 192 TABLE 156 GERMANY: KEY MACROINDICATORS 192 TABLE 157 GERMANY: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 192 TABLE 158 GERMANY: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 193 TABLE 159 GERMANY: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 193 TABLE 160 GERMANY: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 193 TABLE 161 GERMANY: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 194 TABLE 162 FRANCE: KEY MACROINDICATORS 194 TABLE 163 FRANCE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 194 TABLE 164 FRANCE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 195 TABLE 165 FRANCE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 195 TABLE 166 FRANCE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 195 TABLE 167 FRANCE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 196 TABLE 168 ITALY: KEY MACROINDICATORS 196 TABLE 169 ITALY: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 196 TABLE 170 ITALY: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 171 ITALY: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 197 TABLE 172 ITALY: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 197 TABLE 173 ITALY: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 198 TABLE 174 UK: KEY MACROINDICATORS 198 TABLE 175 UK: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 198 TABLE 176 UK: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 177 UK: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 199 TABLE 178 UK: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 199 TABLE 179 UK: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 200 TABLE 180 SPAIN: KEY MACROINDICATORS 200 TABLE 181 SPAIN: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 200 TABLE 182 SPAIN: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 183 SPAIN: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 201 TABLE 184 SPAIN: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 201 TABLE 185 SPAIN: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 202 TABLE 186 SWITZERLAND: KEY MACROINDICATORS 202 TABLE 187 SWITZERLAND: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 202 TABLE 188 SWITZERLAND: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 189 SWITZERLAND: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 203 TABLE 190 SWITZERLAND: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 203 TABLE 191 SWITZERLAND: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 204 TABLE 192 NETHERLANDS: KEY MACROINDICATORS 204 TABLE 193 NETHERLANDS: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 204 TABLE 194 NETHERLANDS: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 205 TABLE 195 NETHERLANDS: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 205 TABLE 196 NETHERLANDS: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 205 TABLE 197 NETHERLANDS: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 206 TABLE 198 REST OF EUROPE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 206 TABLE 199 REST OF EUROPE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 200 REST OF EUROPE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 207 TABLE 201 REST OF EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 207 TABLE 202 REST OF EUROPE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 208 TABLE 203 LATIN AMERICA: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209 TABLE 204 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 209 TABLE 205 LATIN AMERICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 206 LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 210 TABLE 207 LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 210 TABLE 208 LATIN AMERICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 210 TABLE 209 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS) 211 TABLE 210 BRAZIL: KEY MACROINDICATORS 211 TABLE 211 BRAZIL: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 212 TABLE 212 BRAZIL: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 212 TABLE 213 BRAZIL: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 212 TABLE 214 BRAZIL: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 213 TABLE 215 BRAZIL: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 213 TABLE 216 MEXICO: KEY MACROINDICATORS 214 TABLE 217 MEXICO: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 214 TABLE 218 MEXICO: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 219 MEXICO: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 215 TABLE 220 MEXICO: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 215 TABLE 221 MEXICO: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 215 TABLE 222 REST OF LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 216 TABLE 223 REST OF LATIN AMERICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 224 REST OF LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 217 TABLE 225 REST OF LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 217 TABLE 226 REST OF LATIN AMERICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 217 TABLE 227 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 219 TABLE 228 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 219 TABLE 229 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 230 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 220 TABLE 231 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 220 TABLE 232 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 220 TABLE 233 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS) 221 TABLE 234 GCC COUNTRIES: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 221 TABLE 235 GCC COUNTRIES: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 236 GCC COUNTRIES: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 222 TABLE 237 GCC COUNTRIES: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 222 TABLE 238 GCC COUNTRIES: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 222 TABLE 239 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS 223 TABLE 240 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 223 TABLE 241 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 242 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 224 TABLE 243 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 224 TABLE 244 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 225 TABLE 245 UNITED ARAB EMIRATES: KEY MACROINDICATORS 225 TABLE 246 UNITED ARAB EMIRATES: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 226 TABLE 247 UNITED ARAB EMIRATES: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 248 UNITED ARAB EMIRATES: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 226 TABLE 249 UNITED ARAB EMIRATES: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 227 TABLE 250 UNITED ARAB EMIRATES: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 227 TABLE 251 OTHER GCC COUNTRIES: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 228 TABLE 252 OTHER GCC COUNTRIES: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 253 OTHER GCC COUNTRIES: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 228 TABLE 254 OTHER GCC COUNTRIES: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 229 TABLE 255 OTHER GCC COUNTRIES: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 229 TABLE 256 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 230 TABLE 257 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 230 TABLE 258 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 230 TABLE 259 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 231 TABLE 260 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 231 TABLE 261 OVERVIEW OF STRATEGIES DEPLOYED BY KEY APHERESIS COMPANIES, JANUARY 2023–MAY 2026 232 TABLE 262 APHERESIS MARKET: DEGREE OF COMPETITION 235 TABLE 263 APHERESIS MARKET: REGION FOOTPRINT 240 TABLE 264 APHERESIS MARKET: PRODUCT FOOTPRINT 241 TABLE 265 APHERESIS MARKET: TYPE FOOTPRINT 241 TABLE 266 APHERESIS MARKET: TECHNOLOGY FOOTPRINT 242 TABLE 267 APHERESIS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 244 TABLE 268 APHERESIS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 245 TABLE 269 APHERESIS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026 247 TABLE 270 APHERESIS MARKET: DEALS, JANUARY 2023–MAY 2026 248 TABLE 271 APHERESIS MARKET: EXPANSIONS, JANUARY 2023–MAY 2026 250 TABLE 272 TERUMO CORPORATION: COMPANY OVERVIEW 251 TABLE 273 TERUMO CORPORATION: PRODUCTS OFFERED 252 TABLE 274 TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026 254 TABLE 275 TERUMO CORPORATION: DEALS, JANUARY 2023–MAY 2026 254 TABLE 276 TERUMO CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026 255 TABLE 277 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW 257 TABLE 278 FRESENIUS SE & CO. KGAA: PRODUCTS OFFERED 258 TABLE 279 FRESENIUS SE & CO. KGAA: PRODUCT LAUNCHES, JANUARY 2023–MARCH 2026 260 TABLE 280 FRESENIUS SE & CO. KGAA: DEALS, JANUARY 2023–MAY 2026 260 TABLE 281 FRESENIUS SE & CO. KGAA: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 261 TABLE 282 FRESENIUS MEDICAL CARE AG: COMPANY OVERVIEW 262 TABLE 283 FRESENIUS MEDICAL CARE CORPORATION: PRODUCTS OFFERED 263 TABLE 284 FRESENIUS MEDICAL CARE AG: DEALS, JANUARY 2023–MAY 2026 264 TABLE 285 HAEMONETICS CORPORATION: COMPANY OVERVIEW 266 TABLE 286 HAEMONETICS CORPORATION: PRODUCTS OFFERED 267 TABLE 287 HAEMONETICS CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–MARCH 2026 268 TABLE 288 HAEMONETICS CORPORATION: DEALS, JANUARY 2023–MAY 2026 268 TABLE 289 B. BRAUN SE: COMPANY OVERVIEW 270 TABLE 290 BD: COMPANY OVERVIEW 274 TABLE 291 BD: PRODUCTS OFFERED 274 TABLE 292 BD: DEALS, JANUARY 2023–MAY 2026 276 TABLE 293 BD: EXPANSIONS, JANUARY 2023–MARCH 2026 276 TABLE 294 ASAHI KASEI MEDICAL CO., LTD.: COMPANY OVERVIEW 277 TABLE 295 ASAHI KASEI MEDICAL CO., LTD.: PRODUCTS OFFERED 277 TABLE 296 ASAHI KASEI MEDICAL CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 278 TABLE 297 OTSUKA HOLDINGS CO., LTD.: COMPANY OVERVIEW 279 TABLE 298 OTSUKA HOLDINGS CO., LTD: PRODUCTS OFFERED 280 TABLE 299 MEDICA S.P.A: COMPANY OVERVIEW 281 TABLE 300 MEDICA S.P.A: PRODUCTS OFFERED 281 TABLE 301 SUMITOMO BAKELITE CO., LTD.: COMPANY OVERVIEW 282 TABLE 302 SUMITOMO BAKELITE CO., LTD.: PRODUCTS OFFERED 283 TABLE 303 KANEKA CORPORATION: COMPANY OVERVIEW 285 TABLE 304 KANEKA CORPORATION: PRODUCTS OFFERED 286 TABLE 305 KANEKA CORPORATION: DEALS, JANUARY 2023–MAY 2026 288 TABLE 306 KANEKA CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026 288 TABLE 307 VANTIVE: COMPANY OVERVIEW 289 TABLE 308 VANTIVE: PRODUCTS OFFERED 289 TABLE 309 VANTIVE: DEALS, JANUARY 2023–MAY 2026 290 TABLE 310 VANTIVE: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 291 TABLE 311 MILTENYI BIOTEC: COMPANY OVERVIEW 292 TABLE 312 MILTENYI BIOTEC: PRODUCTS OFFERED 292 TABLE 313 MILTENYI BIOTEC: DEALS, JANUARY 2023–MAY 2026 293 TABLE 314 MILTENYI BIOTEC: EXPANSIONS, JANUARY 2023–MARCH 2026 294 TABLE 315 NIKKISO CO., LTD.: COMPANY OVERVIEW 295 TABLE 316 NIKKISO CO., LTD.: PRODUCTS OFFERED 296 TABLE 317 NIKKISO CO., LTD: DEALS, JANUARY 2023–MAY 2026 297 TABLE 318 NIKKISO CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 297 TABLE 319 TORAY INDUSTRIES, INC.: COMPANY OVERVIEW 298 TABLE 320 TORAY INDUSTRIES, INC.: PRODUCTS OFFERED 299 TABLE 321 MACOPHARMA SA: COMPANY OVERVIEW 300 TABLE 322 INFOMED SA: COMPANY OVERVIEW 301 TABLE 323 THERAKOS LLC.: COMPANY OVERVIEW 301 TABLE 324 MEDICAP GMBH: COMPANY OVERVIEW 302 TABLE 325 HAIER BIOMEDICAL: COMPANY OVERVIEW 302 TABLE 326 SICHUAN NIGALE BIOTECHNOLOGY CO, LTD.: COMPANY OVERVIEW 303 TABLE 327 JAFRON BIOMEDICAL CO., LTD.: COMPANY OVERVIEW 304 TABLE 328 SHANGHAI DAHUA MEDICAL APPARATUS CO., LTD: COMPANY OVERVIEW 305 TABLE 329 KENTEC MEDICAL: COMPANY OVERVIEW 306 TABLE 330 SCINOMED LTD.: COMPANY OVERVIEW 306 TABLE 331 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON APHERESIS MARKET 317 FIGURE 1 MARKET SCENARIO 38 FIGURE 2 GLOBAL APHERESIS MARKET, 2024–2031 38 FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN APHERESIS MARKET, 2023–2026 39 FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF APHERESIS MARKET 40 FIGURE 5 HIGH-GROWTH SEGMENTS, 2026–2031 40 FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST GROWTH, IN TERMS OF VALUE, DURING FORECAST PERIOD 41 FIGURE 7 GROWING INCIDENCE OF CHRONIC DISEASES AND WIDER ADOPTION OF THERAPEUTIC APHERESIS TO DRIVE MARKET GROWTH 42 FIGURE 8 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2025 43 FIGURE 9 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 44 FIGURE 10 APHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 45 FIGURE 11 APHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 61 FIGURE 12 APHERESIS MARKET: SUPPLY CHAIN ANALYSIS 65 FIGURE 13 APHERESIS MARKET: VALUE CHAIN ANALYSIS 66 FIGURE 14 APHERESIS MARKET ECOSYSTEM 68 FIGURE 15 REVENUE SHIFT AND NEW REVENUE POCKETS FOR APHERESIS MARKET 75 FIGURE 16 INVESTMENT & FUNDING SCENARIO 76 FIGURE 17 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR APHERESIS PATENTS, JANUARY 2015–MAY 2026 86 FIGURE 18 APHERESIS MARKET: AI USE CASES 91 FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF APHERESIS PRODUCTS 100 FIGURE 20 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS, BY END USER 101 FIGURE 21 NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES, 2025 158 FIGURE 22 NORTH AMERICA: APHERESIS MARKET SNAPSHOT 159 FIGURE 23 ASIA PACIFIC: APHERESIS MARKET SNAPSHOT 168 FIGURE 24 REVENUE ANALYSIS OF KEY PLAYERS, 2023–2025 (USD MILLION) 234 FIGURE 25 GLOBAL MARKET SHARE ANALYSIS, 2025 235 FIGURE 26 US: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 236 FIGURE 27 EUROPE: MARKET SHARE ANALYSIS, 2025 236 FIGURE 28 APHERESIS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 239 FIGURE 29 APHERESIS MARKET: COMPANY FOOTPRINT 240 FIGURE 30 APHERESIS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 244 FIGURE 31 EV/EBITDA OF KEY VENDORS 246 FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 246 FIGURE 33 APHERESIS MARKET: BRAND/PRODUCT COMPARISON 247 FIGURE 34 TERUMO CORPORATION: COMPANY SNAPSHOT (2025) 252 FIGURE 35 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2025) 258 FIGURE 36 FRESENIUS MEDICAL CARE AG: COMPANY SNAPSHOT (2025) 263 FIGURE 37 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2025) 267 FIGURE 38 B. BRAUN SE: COMPANY SNAPSHOT (2025) 271 FIGURE 39 BD: COMPANY SNAPSHOT (2025) 275 FIGURE 40 OTSUKA HOLDINGS CO., LTD: COMPANY SNAPSHOT (2025) 280 FIGURE 41 SUMITOMO BAKELITE CO., LTD.: COMPANY SNAPSHOT (2025) 283 FIGURE 42 KANEKA CORPORATION: COMPANY SNAPSHOT (2025) 286 FIGURE 43 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2025) 296 FIGURE 44 TORAY INDUSTRIES, INC.: COMPANY SNAPSHOT (2025) 299 FIGURE 45 RESEARCH DESIGN 307 FIGURE 46 PRIMARY SOURCES 310 FIGURE 47 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE) 311 FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (DEMAND SIDE) 312 FIGURE 49 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 312 FIGURE 50 GLOBAL MARKET ESTIMATION: SUPPLY-SIDE ANALYSIS (BOTTOM-UP APPROACH) 313 FIGURE 51 APHERESIS MARKET SIZE ANALYSIS, 2025 313 FIGURE 52 MARKET SIZE ESTIMATION FOR APHERESIS: REVENUE SHARE ANALYSIS 314 FIGURE 53 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 315 FIGURE 54 APHERESIS MARKET: CAGR PROJECTIONS, 2026–2031 316 FIGURE 55 DATA TRIANGULATION METHODOLOGY 318

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們